Ferroptosis, a Regulated Form of Cell Death, as a Target for the Development of Novel Drugs Preventing Ischemia/Reperfusion of Cardiac Injury, Cardiomyopathy and Stress-Induced Cardiac Injury

Vyacheslav V. Ryabov,Leonid N. Maslov,Evgeniy V. Vyshlov,Alexander V. Mukhomedzyanov,Mikhail Kilin,Svetlana V. Gusakova,Alexandra E. Gombozhapova,Oleg O. Panteleev
DOI: https://doi.org/10.3390/ijms25020897
IF: 5.6
2024-01-11
International Journal of Molecular Sciences
Abstract:The hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is about 6% and has not decreased in recent years. The leading cause of death of these patients is ischemia/reperfusion (I/R) cardiac injury. It is quite obvious that there is an urgent need to create new drugs for the treatment of STEMI based on knowledge about the pathogenesis of I/R cardiac injury, in particular, based on knowledge about the molecular mechanism of ferroptosis. In this study, it was demonstrated that ferroptosis is involved in the development of I/R cardiac injury, antitumor drug-induced cardiomyopathy, diabetic cardiomyopathy, septic cardiomyopathy, and inflammation. There is indirect evidence that ferroptosis participates in stress-induced cardiac injury. The activation of AMPK, PKC, ERK1/2, PI3K, and Akt prevents myocardial ferroptosis. The inhibition of HO-1 alleviates myocardial ferroptosis. The roles of GSK-3β and NOS in the regulation of ferroptosis require further study. The stimulation of Nrf2, STAT3 prevents ferroptosis. The activation of TLR4 and NF-κB promotes ferroptosis of cardiomyocytes. MiR-450b-5p and miR-210-3p can increase the tolerance of cardiomyocytes to hypoxia/reoxygenation through the inhibition of ferroptosis. Circ_0091761 RNA, miR-214-3p, miR-199a-5p, miR-208a/b, miR-375-3p, miR-26b-5p and miR-15a-5p can aggravate myocardial ferroptosis.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper aims to explore the role of ferroptosis in ischemia/reperfusion (I/R) cardiac injury, cardiomyopathy, and stress - induced cardiac injury, and to target it for the development of new drugs to prevent these cardiac diseases. Specifically, the paper mainly focuses on the following aspects: 1. **Molecular mechanisms of ferroptosis**: Ferroptosis is a form of non - apoptotic cell death caused by iron - dependent lipid peroxidation. The paper describes in detail the main manifestations of ferroptosis, such as cell membrane rupture, protein release, formation of lipid peroxidation products (such as malondialdehyde MDA and 4 - hydroxynonenal 4 - HNE), and decrease in glutathione (GSH) levels. 2. **Role of ferroptosis inhibitors**: The paper discusses several known ferroptosis inhibitors, such as deferoxamine, ferrostatin - 1, UAMC - 3203, dexrazoxane, and liproxstatin - 1. These inhibitors have been proven in experiments to reduce the degree of ferroptosis. 3. **Role of kinases in ferroptosis regulation**: The paper explores in detail the role of multiple kinases in ferroptosis regulation, including AMP - activated protein kinase (AMPK), extracellular signal - regulated kinase 1/2 (ERK1/2), phosphatidylinositol 3 - kinase (PI3K), protein kinase C (PKC), Akt kinase, nitric oxide synthase (NOS), heme oxygenase - 1 (HO - 1), etc. For example, activation of AMPK can inhibit ferroptosis, while activation of GSK - 3β promotes ferroptosis. 4. **Role of non - coding RNAs in ferroptosis regulation**: The paper also discusses the role of non - coding RNAs (especially microRNA, long - non - coding RNA, and circular RNA) in ferroptosis regulation. For example, the miR - 199a - 5p inhibitor can inhibit ferroptosis by activating the Akt signaling pathway, while miR - 15a - 5p promotes ferroptosis by reducing GPX4 expression and increasing MDA and ROS levels. In conclusion, this paper attempts to provide theoretical basis and technical support for the development of new therapeutic drugs by in - depth study of the molecular mechanisms of ferroptosis and its role in cardiac diseases.